Rhea-AI Summary
Palvella Therapeutics and Pieris Pharmaceuticals have announced a definitive merger agreement to create a Nasdaq-listed, clinical-stage biopharmaceutical company. The combined entity will focus on developing novel treatments for rare genetic skin diseases, particularly QTORIN™ 3.9% rapamycin anhydrous gel for microcystic lymphatic malformations (LMs) and cutaneous venous malformations.
Key points:
- Expected $80.5 million in cash at closing, including $78.9 million from private financing
- Cash runway into second half of 2027
- Funding through multiple clinical trial milestones
- QTORIN™ rapamycin has FDA Breakthrough Therapy and Fast Track Designations
- Merger expected to close in Q4 2024, subject to approvals
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
88.6%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.6%
Tags
-
News
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.03%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.06%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.81%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-70.86%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.73%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
-
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6%
Tags
Rhea-AI Summary
Summary not available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.18%
Tags
FAQ
What is the current stock price of PIERIS PHARMACEUTICALS (PIRS)?
PIERIS PHARMACEUTICALS (PIRS) last closed at $13.6.